Active patients with displaced femoral neck fractures are often treated with total hip arthroplasty (THA). However, optimal femoral fixation in these patients is controversial. The purpose of this study was to compare early complication and readmission rates in patients with hip fracture treated with THA receiving cemented vs cementless femoral fixation.
The National Readmissions Database was queried to identify patients undergoing primary THA for femoral neck fracture from 2016 to 2017. Postoperative complications and unplanned readmissions at 30, 90, and 180 days were compared between patients treated with cemented and cementless THA. Univariate and multivariate analyses were performed to compare differences between groups and account for confounding variables.
Of 17,491 patients identified, 4427 (25.3%) received cemented femoral fixation and 13,064 (74.7%) cementless. The cemented group was significantly older (77.2 vs 71.1, P &lt; .001), had more comorbidities (Charlson comorbidity index 4.44 vs 3.92, P &lt; .001), and had a greater proportion of women (70.5% vs 65.2%, P &lt; .001) compared with the cementless group. On multivariate analysis, cemented fixation was associated with reduced rates of periprosthetic fracture (odds ratio 0.052, 95% confidence interval 0.003-0.247, P= .004) at 30 days but similar readmission rates at 30, 90, and 180 days (odds ratio range 1.012-1.114, P &gt; .05) postoperatively compared with cementless fixation. Cemented fixation was associated with greater odds of medical complications at 180 days postoperatively (odds ratio 1.393, 95% confidence interval 1.042-1.862, P= .025).
Cemented femoral fixation was associated with a lower short-term incidence of periprosthetic fractures, higher incidence of medical complications, and equivalent unplanned readmission rates within 180 days postoperatively compared with cementless fixation in patients undergoing THA for femoral neck fracture.
Level III.
Level III.Medical progress in cancer care has led to increased life expectancy outcomes across all stages of cancer, including in advanced cancers. People now living with advanced chronic cancers have unique, ongoing functional and quality-of-life needs. This article explores the functional considerations of individuals living with advanced chronic cancers in terms of managing chronic palliative care needs, assessing and intervening for functional issues, and consistently using occupational therapy in shared service provision together with medical and nursing teams. The unique and changing functional needs of these individuals may be effectively addressed through consideration of chronic palliative approaches to care; earlier access to occupational therapy services to facilitate continued engagement in everyday activities; and shared service provision with nursing to address both medical wellness and functional status.
These include key databases (Pubmed, CINAHL), international guidelines, and professional guidance documents.
Individuals living with advanced chronic cancer have ongoing and fluctuating functional needs that should be addressed in palliative care service provision. The inclusion of occupational therapy as part of inter- and multidisciplinary teams can facilitate maximization of function for individuals living with advanced chronic cancer.
Timely early referrals to occupational therapy can address functional issues as they arise, and can prepare individuals for future functional considerations.
Timely early referrals to occupational therapy can address functional issues as they arise, and can prepare individuals for future functional considerations.Older patients with cancer present many symptoms during treatment. One of those symptoms is fatigue, which may be caused by factors unrelated to cancer. One of those factors is frailty increased with age. Frailty and fatigue affect older patients with cancer physically, psychosocially, emotionally, and spiritually. This study investigated the relationship between frailty and fatigue in older patients with cancer.
This descriptive study was conducted between July 15, 2019, and February 15, 2020, in the medical oncology polyclinic and the medical oncology outpatient treatment unit of a university hospital. The sample consisted of voluntary 288 patients who met inclusion criteria. Data were collected using a demographic questionnaire and the Edmonton Frail Scale (EFS), and the Cancer Fatigue Scale (CFS).
The mean age of participants was 71.71 ± 5.29 years. Participants had a mean EFS score of 6 ± 3.21. Of participants, 36.1% were not frail, while 20.1% were vulnerable, 19.1% moderately frail, 17.7% mildly frail, and 6.9% severely frail. Participants had a mean CFS score of 21.41 ± 12.25. There was a positive correlation between EFS and CFS scores (P?=?.000, r?=?0.734). Of participants, 63.8% were frail with physical and cognitive fatigue. The higher the frailty, the higher the fatigue.
Elderly patients with cancer appear to be fragile, with frailty causing fatigue and many other conditions. It is important to determine the frailty and fatigue of elderly patients with cancer. It is essential understand the relationship between the frailty and fatigue for effective and correct management of nursing care.
Elderly patients with cancer appear to be fragile, with frailty causing fatigue and many other conditions. It is important to determine the frailty and fatigue of elderly patients with cancer. It is essential understand the relationship between the frailty and fatigue for effective and correct management of nursing care.Momordica charantia or bitter melon is a well-known vegetable with a number of therapeutic actions in Ayurvedic medicine. Alpha-eleostearic acid, a conjugated trienoic fatty acid present in bitter melon is proven to have anticancer properties. https://www.selleckchem.com/products/Rapamycin.html Crude seed oil from local bitter melon varieties could be an effective and economical anticancer therapy.
The study was conducted to evaluate the anticancer effect of the crude oil from the seeds of Matale green variety of bitter melon on a hepatocellular carcinoma-induced rat model.
Hepatocellular carcinoma (HCC) was experimentally induced in Wistar rats. Crude seed oil of Matale green bitter melon (MGBM) was supplemented to one treatment group in concurrence with carcinoma induction and to another treatment group after the development of carcinoma. After 168 days, gross morphological, histopathological, biochemical, hematological and gene-expression analysis of treated and control groups were performed.
Oral supplementation of MGBM seed oil showed a statistically significant reduction (p&lt;0.